142 related articles for article (PubMed ID: 35868407)
1. Increased expression of matrix metalloproteinases 2 and 9 as poor prognosis factor for Hodgkin's lymphoma patients.
Silva BO; Medeiros JW; Albuquerque GS; Valderrama PM; Barbosa AHQ; de Souza JM; Oliveira RS; Morais AL; Neto JDCS; Muniz MTC
J Pediatr (Rio J); 2023; 99(1):59-64. PubMed ID: 35868407
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in Hodgkin's and non-Hodgkin's lymphoma.
Hazar B; Polat G; Seyrek E; Bağdatoğlğlu O; Kanik A; Tiftik N
Int J Clin Pract; 2004 Feb; 58(2):139-43. PubMed ID: 15055861
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of angiogenic cytokines in childhood Hodgkin lymphoma.
Citak EC; Oguz A; Karadeniz C; Akyurek N
Pathol Res Pract; 2008; 204(2):89-96. PubMed ID: 18207652
[TBL] [Abstract][Full Text] [Related]
4. Expression of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in tissues with a diagnosis of childhood lymphoma.
Bozkurt C; Ertem U; Oksal A; Sahin G; Yüksek N; Birgen D
Pediatr Hematol Oncol; 2008 Sep; 25(7):621-9. PubMed ID: 18850474
[TBL] [Abstract][Full Text] [Related]
5. Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma.
Kuittinen O; Soini Y; Turpeenniemi-Hujanen T
Eur J Haematol; 2002 Oct; 69(4):205-12. PubMed ID: 12431239
[TBL] [Abstract][Full Text] [Related]
6. Gelatinases (MMP-2 and MMP-9), TIMP-1 expression and the extent of neovascularization in aggressive non-Hodgkin's lymphomas.
Kuittinen O; Apaja-Sarkkinen M; Turpeenniemi-Hujanen T
Eur J Haematol; 2003 Aug; 71(2):91-9. PubMed ID: 12890147
[TBL] [Abstract][Full Text] [Related]
7. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy.
Unsal D; Akyurek N; Uner A; Erpolat OP; Han U; Akmansu M; Mentes BB; Dursun A
Am J Clin Oncol; 2008 Feb; 31(1):55-63. PubMed ID: 18376229
[TBL] [Abstract][Full Text] [Related]
8. Expression of the matrix metalloproteinase 9 in Hodgkin's disease is independent of EBV status.
Flavell JR; Baumforth KR; Williams DM; Lukesova M; Madarova J; Noskova V; Prochazkova J; Lowe D; Kolar Z; Murray PG; Nelson PN
Mol Pathol; 2000 Jun; 53(3):145-9. PubMed ID: 10897334
[TBL] [Abstract][Full Text] [Related]
9. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
10. LGALS3 as a prognostic factor for classical Hodgkin's lymphoma.
Koh YW; Jung SJ; Park CS; Yoon DH; Suh C; Huh J
Mod Pathol; 2014 Oct; 27(10):1338-44. PubMed ID: 24603587
[TBL] [Abstract][Full Text] [Related]
11. High expression of matrix metalloproteinases: MMP-2 and MMP-9 predicts poor survival outcome in colorectal carcinoma.
Salem N; Kamal I; Al-Maghrabi J; Abuzenadah A; Peer-Zada AA; Qari Y; Al-Ahwal M; Al-Qahtani M; Buhmeida A
Future Oncol; 2016 Feb; 12(3):323-31. PubMed ID: 26814712
[TBL] [Abstract][Full Text] [Related]
12. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
Kirimlioğlu H; Türkmen I; Başsüllü N; Dirican A; Karadağ N; Kirimlioğlu V
Turk J Gastroenterol; 2009 Mar; 20(1):41-7. PubMed ID: 19330734
[TBL] [Abstract][Full Text] [Related]
13. [Expression of CD147 and matrix metalloproteinase-9 in children with non-Hodgkin's lymphoma and its correlation with prognosis].
Liu AG; Hu Q; Tao HF; Liu SY; Zhang LQ; Hu Y
Zhonghua Er Ke Za Zhi; 2009 Oct; 47(10):785-8. PubMed ID: 20021816
[TBL] [Abstract][Full Text] [Related]
14. Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer.
Zhang B; Cao X; Liu Y; Cao W; Zhang F; Zhang S; Li H; Ning L; Fu L; Niu Y; Niu R; Sun B; Hao X
BMC Cancer; 2008 Mar; 8():83. PubMed ID: 18373849
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer.
Schwandner O; Schlamp A; Broll R; Bruch HP
Int J Colorectal Dis; 2007 Feb; 22(2):127-36. PubMed ID: 16896992
[TBL] [Abstract][Full Text] [Related]
16. Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma.
de Vicente JC; Fresno MF; Villalain L; Vega JA; Hernández Vallejo G
Oral Oncol; 2005 Mar; 41(3):283-93. PubMed ID: 15743691
[TBL] [Abstract][Full Text] [Related]
17. Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas.
Ramachandran RK; Sørensen MD; Aaberg-Jessen C; Hermansen SK; Kristensen BW
PLoS One; 2017; 12(2):e0172234. PubMed ID: 28234925
[TBL] [Abstract][Full Text] [Related]
18. Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage.
Aglund K; Rauvala M; Puistola U; Angström T; Turpeenniemi-Hujanen T; Zackrisson B; Stendahl U
Gynecol Oncol; 2004 Sep; 94(3):699-704. PubMed ID: 15350361
[TBL] [Abstract][Full Text] [Related]
19. The role of vascular endothelial growth factor and matrix metalloproteinases in canine lymphoma: in vivo and in vitro study.
Aricò A; Giantin M; Gelain ME; Riondato F; Comazzi S; Rütgen BC; Essler SE; Dacasto M; Castagnaro M; Aresu L
BMC Vet Res; 2013 May; 9():94. PubMed ID: 23641796
[TBL] [Abstract][Full Text] [Related]
20. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
